A head-to-head comparison of 7-day and 5-day treatment schedule of azacitidine in patients with higher risk myelodysplastic syndromes revealed trends in overall survival and time to transformation to leukemia.
Findings from a retrospective study identified risk factors for thrombosis in patients with post-polycythemia vera myelofibrosis, compared with patients with polycythemia vera.
A team of researchers presented their strategies for choosing patients with myelofibrosis who may be candidates for allogeneic stem cell transplantation and guiding their treatment.
